West Pharma (WST) Tops Q4 EPS by 13c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q4 EPS of $2.04, $0.13 better than the analyst estimate of $1.91. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $710.2 million.
GUIDANCE:
West Pharma sees FY2022 EPS of $9.20-$9.35, versus the consensus of $9.06. West Pharma sees FY2022 revenue of $3.05-3.075 billion, versus the consensus of $3.07 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Regal Rexnord Corporation (RRX) Tops Q3 EPS by 25c ; Offers Guidance
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
